Five things for pharma marketers to know: Wednesday, November 23, 2016

1. Eli Lilly's solanezumab, an experimental treatment for Alzheimer's disease, failed to slow cognitive decline in patients with mild symptoms in a clinical trial. The drug has already failed in two other trials. Lilly CEO John Lechleiter released a video statement thanking the patients who participated in the trial. (NYT)

2. Juno Therapeutics said two more patients died during a trial testing its experimental CAR-T therapy drug as a treatment for leukemia. Juno, Kite Pharma, and Novartis are developing CAR-T therapies. (Reuters)

3. The New England Journal of Medicine launched a digital platform for healthcare professionals in China. It has partnered with the Jiahui Medical Research and Education Group. (NEJM)

4. The FDA added a black-box warning to Essure, an implantable medical device used to prevent pregnancy marketed by Bayer. Some patients had urged the FDA to withdraw the device from the market over safety concerns. (NYT)

5. Children as young as two years old are influenced by TV ads for snacks. Children watching TV shows with ads for snack foods were more likely to consume more calories as they watched than kids who were showed ads for department stores. (Reuters)